BioMarin Pharmaceutical Inc. (BMRN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - BioMarin is optimistic about its growth trajectory in 2026, building on a strong performance in 2025 with total revenue growth of 13% [1] - The skeletal conditions business unit, which includes Voxzogo, experienced significant growth of 26% in 2025, while enzyme therapies grew by 9% [1] Corporate Strategy - The company's corporate strategy is framed around three pillars: growth, innovation, and value commitment [2] - BioMarin anticipates strong growth from both its skeletal conditions and enzyme therapies business units, with guidance indicating high single-digit growth for both [2] - The expected closing of the Amicus acquisition in Q2 is anticipated to enhance the portfolio with two high-growth products [2]